In this video, you will explore more about how Mounjaro (Tirezapetide) helped people with Type 2 Diabetes Mellitus in SURPASS-2 Trail.
SURPASS-2: a 40-weeks, randomized, open-label, phase 3 trial, comparing Mounjaro vs semaglutide in 1879 adults with T2DM inadequately controlled on metformin.
Disclaimer
This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)
For adverse events and safety reporting: email: [email protected]
24 /7 mobile : +966 567 868 843 working hours: +966 11 461 7800 , Ext: 1
For Lilly product information: email: [email protected]
For further information, please contact:
Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: [email protected]
Please go to PDF Material for prescribing information
PP-TR-SA-0047
